Dietary fat increases quercetin bioavailability in overweight adults

Molecular Nutrition and Food Research

Volumn 57, Issue 5, 2013, Pages 896-905

  Guo, Yi ^a,b   Mah, Eunice ^a   Davis, Catherine G ^a   Jalili, Thunder ^c   Ferruzzi, Mario G ^d   Chun, Ock K ^a   Bruno, Richard S ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Fat; Micellarization efficiency; Obesity; Pharmacokinetics; Quercetin

Indexed keywords

3-METHYLQUERCETIN; BIOLOGICAL MARKER; DISACCHARIDE; DRUG DERIVATIVE; QUERCETIN; QUERCETIN 3 METHYL ETHER; TAMARIXETIN;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FAT INTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIETARY FATS; DISACCHARIDES; FEMALE; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; OVERWEIGHT; OXIDATIVE STRESS; QUERCETIN;

EID: 84876446335     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200619     Document Type: Article

References (58)

1. Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J. et al., Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125, e2-e220.
2. Atsma, F., Bartelink, M. L., Grobbee, D. E., van der Schouw, Y. T., Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13, 265-279.
3. Wilson, P. W., D'Agostino, R. B., Sullivan, L., Parise, H. et al., Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 2002, 162, 1867-1872.
4. Kris-Etherton, P. M., Hecker, K. D., Bonanome, A., Coval, S. M. et al., Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 2002, 113(Suppl 9B), 71S-88S.
5. Harnly, J. M., Doherty, R. F., Beecher, G. R., Holden, J. M. et al., Flavonoid content of U.S. fruits, vegetables, and nuts. J. Agric. Food Chem. 2006, 54, 9966-9977.
6. Knekt, P., Kumpulainen, J., Jarvinen, R., Rissanen, H. et al., Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 2002, 76, 560-568.
7. Yochum, L., Kushi, L. H., Meyer, K., Folsom, A. R., Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am. J. Epidemiol. 1999, 149, 943-949.
8. Conquer, J. A., Maiani, G., Azzini, E., Raguzzini, A. et al., Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 1998, 128, 593-597.
9. Knab, A. M., Shanely, R. A., Henson, D. A., Jin, F. et al., Influence of quercetin supplementation on disease risk factors in community-dwelling adults. J. Am. Diet Assoc. 2011, 111, 542-549.
10. Edwards, R. L., Lyon, T., Litwin, S. E., Rabovsky, A. et al., Quercetin reduces blood pressure in hypertensive subjects. J. Nutr. 2007, 137, 2405-2411.
11. Egert, S., Bosy-Westphal, A., Seiberl, J., Kurbitz, C. et al., Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 2009, 102, 1065-1074.
12. Larson, A., Witman, M. A., Guo, Y., Ives, S. et al., Acute, quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower plasma angiotensin-converting enzyme activity or endothelin-1: nitric oxide. Nutr. Res. 2012, 32, 557-564.
13. Harwood, M., Danielewska-Nikiel, B., Borzelleca, J. F., Flamm, G. W. et al., A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 2007, 45, 2179-2205.
14. Graefe, E. U., Wittig, J., Mueller, S., Riethling, A. K. et al., Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 2001, 41, 492-499.
15. Ader, P., Wessmann, A., Wolffram, S., Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic. Biol. Med. 2000, 28, 1056-1067.
16. Manach, C., Scalbert, A., Morand, C., Remesy, C. et al., Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727-747.
17. Arts, I. C., Sesink, A. L., Faassen-Peters, M., Hollman, P. C., The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides. Br. J. Nutr. 2004, 91, 841-847.
18. Egert, S., Wolffram, S., Schulze, B., Langguth, P. et al., Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules. Br. J. Nutr. 2012, 107, 539-546.
19. Nishijima, T., Iwai, K., Saito, Y., Takida, Y. et al., Chronic ingestion of apple pectin can enhance the absorption of quercetin. J. Agric. Food Chem. 2009, 57, 2583-2587.
20. Lesser, S., Cermak, R., Wolffram, S., Bioavailability of quercetin in pigs is influenced by the dietary fat content. J. Nutr. 2004, 134, 1508-1511.
21. Lesser, S., Cermak, R., Wolffram, S., The fatty acid pattern of dietary fat influences the oral bioavailability of the flavonol quercetin in pigs. Br. J. Nutr. 2006, 96, 1047-1052.
22. Liao, K., Yin, M., Individual and combined antioxidant effects of seven phenolic agents in human erythrocyte membrane ghosts and phosphatidylcholine liposome systems: importance of the partition coefficient. J. Agric. Food Chem. 2000, 48, 2266-2270.
23. Azuma, K., Ippoushi, K., Ito, H., Higashio, H. et al., Combination of lipids and emulsifiers enhances the absorption of orally administered quercetin in rats. J. Agric. Food Chem. 2002, 50, 1706-1712.
24. U.S. Department of Agriculture, Agricultural Research Service, USDA Database for the Flavonoid Content of Selected Foods, Release 3.0. 2011.
25. Moon, Y. J., Wang, L., DiCenzo, R., Morris, M. E., Quercetin pharmacokinetics in humans. Biopharm. Drug Dispos. 2008, 29, 205-217.
26. Nemeth, K., Plumb, G. W., Berrin, J. G., Juge, N. et al., Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr. 2003, 42, 29-42.
27. U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary Guidelines for Americans, U.S Government Printing Office, Washington, DC 2010.
28. Mullen, W., Edwards, C. A., Crozier, A., Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br. J. Nutr. 2006, 96, 107-116.
29. Carlstrom, J., Symons, J. D., Wu, T. C., Bruno, R. S. et al., A quercetin supplemented diet does not prevent cardiovascular complications in spontaneously hypertensive rats. J. Nutr. 2007, 137, 628-633.
30. Huang, D., Ou, B., Hampsch-Woodill, M., Flanagan, J. A. et al., High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fluorescence reader in 96-well format. J. Agric. Food Chem. 2002, 50, 4437-4444.
31. Bruno, R. S., Ramakrishnan, R., Montine, T. J., Bray, T. M. et al., {alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. Am. J. Clin. Nutr. 2005, 81, 95-103.
32. Bruno, R. S., Dugan, C. E., Smyth, J. A., DiNatale, D. A. et al., Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J. Nutr. 2008, 138, 323-331.
33. Leonard, S. W., Bruno, R. S., Paterson, E., Schock, B. C. et al., 5-Nitro-gamma-tocopherol increases in human plasma exposed to cigarette smoke in vitro and in vivo. Free Radic. Biol. Med. 2003, 35, 1560-1567.
34. Mah, E., Noh, S. K., Ballard, K. D., Matos, M. E. et al., Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine: arginine. J. Nutr. 2011, 141, 1961-1968.
35. Kean, E. G., Hamaker, B. R., Ferruzzi, M. G., Carotenoid bioaccessibility from whole grain and degermed maize meal products. J. Agric. Food Chem. 2008, 56, 9918-9926.
36. Bland, J. M., Altman, D. G., Calculating correlation coefficients with repeated observations: part 1-correlation within subjects. BMJ 1995, 310, 446.
37. Boots, A. W., Haenen, G. R., Bast, A., Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol. 2008, 585, 325-337.
38. Mah, E., Matos, M. D., Kawiecki, D., Ballard, K. et al., Vitamin C status is related to proinflammatory responses and impaired vascular endothelial function in healthy, college-aged lean and obese men. J. Am. Diet Assoc. 2011, 111, 737-743.
39. Boots, A. W., Drent, M., de Boer, V. C., Bast, A. et al., Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin. Nutr. 2011, 30, 506-512.
40. Egert, S., Wolffram, S., Bosy-Westphal, A., Boesch-Saadatmandi, C. et al., Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J. Nutr. 2008, 138, 1615-1621.
41. Shanely, R. A., Knab, A. M., Nieman, D. C., Jin, F. et al., Quercetin supplementation does not alter antioxidant status in humans. Free Radic. Res. 2010, 44, 224-231.
42. Gentilcore, D., Chaikomin, R., Jones, K. L., Russo, A. et al., Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J. Clin. Endocrinol. Metab. 2006, 91, 2062-2067.
43. de Wit, N., Derrien, M., Bosch-Vermeulen, H., Oosterink, E. et al., Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, G589-G599.
44. Schoefer, L., Mohan, R., Schwiertz, A., Braune, A. et al., Anaerobic degradation of flavonoids by Clostridium orbiscindens. Appl. Environ. Microbiol. 2003, 69, 5849-5854.
45. Ibarra, M., Moreno, L., Vera, R., Cogolludo, A. et al., Effects of the flavonoid quercetin and its methylated metabolite isorhamnetin in isolated arteries from spontaneously hypertensive rats. Planta. Med. 2003, 69, 995-1000.
46. Wright, B., Moraes, L. A., Kemp, C. F., Mullen, W. et al., A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br. J. Pharmacol. 2010, 159, 1312-1325.
47. Egert, S., Boesch-Saadatmandi, C., Wolffram, S., Rimbach, G. et al., Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J. Nutr. 2010, 140, 278-284.
48. Moon, J. H., Nakata, R., Oshima, S., Inakuma, T. et al., Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279, R461-467.
49. Madsen, J. L., Effects of gender, age, and body mass index on gastrointestinal transit times. Dig. Dis. Sci. 1992, 37, 1548-1553.
50. Mannisto, P. T., Kaakkola, S., Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51, 593-628.
51. Suzuki, H., Sugiyama, Y., Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 2002, 54, 1311-1331.
52. Blumberg, J. B., Chen, O., in: Merskin, M. S., Bidlack, W. R., Randolph, R. K., (Eds.), Phytochemcals: Aging and Health, CRC Press, Taylor & Francis Group, Boca Raton, FL 2008, pp. 19-37.
53. Junqueira, V. B., Barros, S. B., Chan, S. S., Rodrigues, L. et al., Aging and oxidative stress. Mol. Aspects Med. 2004, 25, 5-16.
54. Bolling, B. W., Court, M. H., Blumberg, J. B., Chen, C. Y., Microsomal quercetin glucuronidation in rat small intestine depends on age and segment. Drug Metab. Dispos. 2011, 39, 1406-1414.
55. Brill, M. J., Diepstraten, J., van Rongen, A., van Kralingen, S. et al., Impact of obesity on drug metabolism and elimination in adults and children. Clin. Pharmacokinet. 2012, 51, 277-304.
56. Goldstein, S. L., Klaus, G., Friedman, D. F., Kim, H. C., in: Warady, B. A., Schaefer, F., Alexander, S. R. (Eds.), Pediatric Dialysis, Springer Science+Business Media, New York, NY 2012, pp. 775-796.
57. Bock, K. W., Eckle, T., Ouzzine, M., Fournel-Gigleux, S., Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in Caco-2 cells. Biochem. Pharmacol. 2000, 59, 467-470.
58. Rothwell, J. A., Day, A. J., Morgan, M. R., Experimental determination of octanol-water partition coefficients of quercetin and related flavonoids. J. Agric Food Chem. 2005, 53, 4355-4360.